Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT103
- Development stage
- Preclinical
- Lead developer
- Mthera Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral, Intraperitoneal
01
Overview
MT103 is an investigational drug candidate currently in preclinical development by Mthera Pharma for the treatment of Type 2 diabetes. The asset is developed using Mthera's proprietary Multi-Component Multi-Target (MCMT) technology platform, which aims to create synergistic therapeutic effects by targeting multiple biological pathways simultaneously. While specific molecular targets and the exact chemical composition have not been publicly disclosed, the MCMT approach typically involves standardized, multi-component botanical extracts or natural product-derived compounds designed to address the complex pathophysiology of metabolic disorders.
Beyond the preview
Go deeper on MT103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT103.